NAPROXEN - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for naproxen and what is the scope of freedom to operate?

Naproxen is the generic ingredient in twelve branded drugs marketed by Atnahs Pharma Us, Amneal, Hetero Labs Ltd Iii, Hikma, Novitium Pharma, Actavis Elizabeth, Aurobindo Pharma Usa, Fosun Pharma, Nuvo Pharms Inc, Pliva, Teva, Trupharma, Adaptis, Amneal Pharms Ny, Aurobindo Pharma, Chartwell Molecules, Dava Pharms Inc, Glenmark Pharms Ltd, Granules, Hamilton Pharms, Hikma Intl Pharms, Invagen Pharms, Ivax Sub Teva Pharms, L Perrigo Co, Norvium Bioscience, Purepac Pharm, Roxane, Sciegen Pharms Inc, Teva Pharms, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Bionpharma, Catalent, Patheon Softgels, Puracap Pharm Llc, Strides Pharma, Twi Pharms, Actavis Labs Fl Inc, Bayer, Able, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Granules India, Hetero Labs Ltd V, Lnk Intl Inc, Marksans Pharma, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Sandoz, Sun Pharm Inds Ltd, Yichang Humanwell, Rising, Sun Pharm, and Currax, and is included in ninety NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are forty-two drug master file entries for naproxen. Fifty-eight suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for NAPROXEN

US Patents:	6
Tradenames:	12
Applicants:	58
NDAs:	90
Drug Master File Entries:	42
Finished Product Suppliers / Packagers:	58
Raw Ingredient (Bulk) Api Vendors:	135
Clinical Trials:	323
Patent Applications:	3,391
Drug Prices:	Drug price trends for NAPROXEN
Drug Sales Revenues:	Drug sales revenues for NAPROXEN
What excipients (inactive ingredients) are in NAPROXEN?	NAPROXEN excipients list
DailyMed Link:	NAPROXEN at DailyMed

See drug prices for NAPROXEN

See drug sales revenues for NAPROXEN

Recent Clinical Trials for NAPROXEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mclean Hospital	Phase 4
United States Department of Defense	Phase 4
Johnson & Johnson Consumer Inc. (J&JCI)	Phase 1

See all NAPROXEN clinical trials

Generic filers with tentative approvals for NAPROXEN

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	375MG	TABLET;ORAL
⤷ Sign Up	⤷ Sign Up	250MG	TABLET;ORAL
⤷ Sign Up	⤷ Sign Up	500MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for NAPROXEN

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Medical Subject Heading (MeSH) Categories for NAPROXEN

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Gout Suppressants

US Patents and Regulatory Information for NAPROXEN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Novelgenix Theraps	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	207612-001	Nov 16, 2018		OTC	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Chartwell Molecules	NAPROXEN	naproxen	TABLET;ORAL	074410-002	Apr 28, 1995		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Purepac Pharm	NAPROXEN	naproxen	TABLET;ORAL	074263-002	Dec 21, 1993		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ivax Sub Teva Pharms	NAPROXEN	naproxen	TABLET;ORAL	074111-002	Feb 28, 1995		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NAPROXEN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Atnahs Pharma Us	NAPROSYN	naproxen	SUSPENSION;ORAL	018965-001	Mar 23, 1987	⤷ Sign Up	⤷ Sign Up
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Atnahs Pharma Us	NAPROSYN	naproxen	TABLET;ORAL	017581-004	Apr 15, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.